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Abstract
Macaques are a potentially useful non-human primate model to compare memory T-cell immunity to acute virus pathogens
such as influenza virus and effector T-cell responses to chronic viral pathogens such as SIV. However, immunological
reagents to study influenza CD8+ T-cell responses in the macaque model are limited. We recently developed an influenza-
SIV vaccination model of pigtail macaques (Macaca nemestrina) and used this to study both influenza-specific and SIV-
specific CD8+ T-cells in 39 pigtail macaques expressing the common Mane-A*10+ (Mane-A01*084) MHC-I allele. To perform
comparative studies between influenza and SIV responses a common influenza nucleoprotein-specific CD8+ T-cell response
was mapped to a minimal epitope (termed RA9), MHC-restricted to Mane-A*10 and an MHC tetramer developed to study
this response. Influenza-specific memory CD8+ T-cell response maintained a highly functional profile in terms of multitude
of effector molecule expression (CD107a, IFN-c, TNF-a, MIP-1b and IL-2) and showed high avidity even in the setting of SIV
infection. In contrast, within weeks following active SIV infection, SIV-specific CD8+ effector T-cells expressed fewer
cytokines/degranulation markers and had a lower avidity compared to influenza specific CD8+ T-cells. Further, the influenza
specific memory CD8 T-cell response retained stable expression of the exhaustion marker programmed death-marker-1 (PD-
1) and co-stimulatory molecule CD28 following infection with SIV. This contrasted with the effector SIV-specific CD8+ T-cells
following SIV infection which expressed significantly higher amounts of PD-1 and lower amounts of CD28. Our results
suggest that strategies to maintain a more functional CD8+ T-cell response, profile may assist in controlling HIV disease.
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Introduction
Chronic viral pathogens such as HIV pose a major challenge to
immune control. CD8 T cell responses partially control viral
replication in both the acute and chronic phase of HIV and SIV
infections. Evidence demonstrating the partial role of CD8 T cells
in HIV/SIV include: depletion of CD8 T-cells in SIV-infected
macaques increasing viral replication [1,2,3,4], control of viral
replication coinciding with the expansion of HIV/SIV-specific
CD8 T cells [5,6], immune pressure exerted by CD8 T cells leads
to viral escape [7] and MHC alleles such as HLA-B*57 and HLA-
B*27 being overrepresented long term non-progressor subjects
[8,9,10,11]. Although CD8 T cell responses are clearly important,
the key characteristics of a protective CD8 T-cell response remain
rather poorly defined. Numerous HIV vaccine studies show that
the magnitude of this response correlates weakly with protection
[2,12,13]. Recent studies have therefore included the measure-
ments of quality and avidity. Quality of the response is commonly
measured by breadth of expression of effector molecules such as
IFN-c, TNF-a, CD107a, IL-2 and MIP-1b [14,15,16] and avidity
as exhibited by ability of MHC class I tetramer to dissociate over
time [17,18]. High avidity HIV-specific CD8 T cells have recently
been shown to be more effective at clearing virus infection [13,19].
In addition, other characteristics such as the memory phenotype,
and kinetics of the CD8 T cell response are also likely to be very
important [20,21]. HIV-specific CD8 T cells present during
chronic infection tend to express an ‘‘exhausted’’ phenotype with
high PD-1 and low CD28 expression and are unable to proliferate
in response to high concentrations of antigen [22,23,24,25,26].
A key problem with studying HIV-specific CD8 T cells is that
these responses are generally unable to prevent the establishment
of chronic infection. This contrasts with CD8 T cell responses to
acute viral infections, such as influenza, where the CTL response is
clearly linked to assisting the resolution of infection [27]. Lessons
on immune control can likely be learnt from studies of acute
infections where the CD8 T cell response assists in resolving the
infection. There are however only a limited number of studies that
have compared memory T-cell response to resolve acute viral
infection to effector T-cell response to a chronic viral pathogen
such as HIV. One such study that has investigated the
characteristics of T-cells in response to HIV and influenza in
humans is Betts et. al. using intracellular cytokine staining
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techniques of CD8 T cell responses following stimulation with
peptide pools [14]. In this study it was shown that effector molecule
production by HIV-specific CD8 T cells is an important factor in
limiting HIV viral load. Furthermore, the total memory influenza-
specific CD8 T cells from subjects with progressive HIV infection
can express multiple effector molecules whereas HIV-specific CD8
T-cells in the same individuals are poorly functional [14].
Elucidating the differences between the CTL responses to these
different viruses should provide insights into what qualities generate
an effective CD8 T cell responses. However such comparative
studies of influenza and HIV responses in humans is difficult as the
timing of either influenza or HIV infection cannot be defined or
controlled. Macaques are a well-established model for HIV
infection and are increasingly used as a model for influenza
infection [28,29,30,31,32]. However reagents for accurately
studying CD8 T cell responses to influenza infection in macaques,
such as MHC class I tetramers, are currently non-existent.
Advances in the SIV-pigtail macaque (M. Nemestrina) model of
HIV infection have led to the characterization of the MHC class I
alleles and the mapping of SIV CD8 T cell epitopes. This has in
turn led to the generation of MHC I tetramer reagents to study
SIV-specific CD8 T cells [33,34,35]. Although MHC class I
tetramers have been developed for both humans and the mouse
model of influenza infection, this is not the case for the non-human
primate or ferret models of influenza infection where there is a lack
of mapped influenza-specific responses [22,36]. Identifying
influenza CD8 T cell epitopes restricted by common MHC I
alleles in this model will enable the production of influenza-specific
tetramers. Since macaques are the only model in which both
influenza and SIV can be studied simultaneously, developing
influenza tetramer reagents will facilitate characterizing of the
quality of the memory influenza-specific CD8 T cell responses in
pigtail macaques and enable more precise comparisons to be made
between the quality of influenza- and SIV-specific CD8 T cells.
Such advances would in turn allow an improved analysis of
functional characteristics that make up a robust antiviral immune
response in order to apply this to future HIV vaccine strategies.
We therefore developed important immunologic reagents and
then studied the quality of the memory influenza-specific CTL
responses after influenza infection in comparison to SIV-specific
CTL responses either after vaccination or during chronic SIV
infection.
Materials and Methods
Animals
We studied a total 39 pigtail macaques (Macaca nemestrinca) for
CD8 T-cell immune responses to SIV and influenza viruses. All
animals expressed the MHC class I allele Mane-A*10 (recently
renamed Mane-A1*08401) as confirmed using allele specific PCR
reactions and/or high-throughput sequencing [37,38,39]. The 39
pigtail macaques studied comprised (Table 1): 17 macaques
inoculated with control influenza A viruses (n = 5) or influenza A
viruses expressing SIV-CTL epitopes (n = 12, see below for
description of viruses, 2 animals previously reported [28]); 8
previously reported SIV-infected Mane-A*10+animals infected
with influenza viruses after SIV infection [28]; 8 influenza-
uninfected Mane-A*10+control animals; and an additional 6 Mane-
A*10+animals previously reported that were administered DNA
and Fowlpox virus expressing SIV-Gag antigens to analyze SIV-
specific CTL responses in the absence of SIV infection [40]. Prior
to any procedures animals were anesthetized intramuscularly with
ketamine (10 mg/kg). All studies were approved by the relevant
animal ethics committees.
Recombinant influenza-SIV constructs
The recombinant influenza A viruses used were generated using
an eight-plasmid reverse genetics system as previously outlined
[28,41,42,43,44]. Briefly, the DNA construct contained eight
influenza virus segments including a genetically manipulated NA
segment containing one Mane-A*10 restricted CD8 T cell epitope
sequence; KP9 (SIV Gag164–172), KVA10 (SIV Tat114–123) or
KSA10 (SIV Tat87–96). The CD8 T cell epitopes were inserted
separately into the NA stalks using the recombinant PCR
techniques [42]. Two mouse-adapted strains of influenza A virus
were used in the study X-31 (H3N2, A/HKx31) and PR8 (H1N1,
A/Puerto Rico/8/1939), these viruses share the same internal
gene segments however differ in their surface glycoprotein HA and
NA genes. 3 separate constructs of each virus (either PR8 and X-
31) were administered to the vaccine animals. The retention of the
Table 1. Mane-A*10+ pigtail macaques studied for Influenza- and SIV-specific CD8 T cell responses.
Group n Influenza Infection Influenza recombinants used SIV infection Comment Reference
Influenza-SIV
vaccine trial
17 PR8 twice, X31 twice over
17 weeks (see Fig. 4).
Wild type influenza (n = 5),
influenza expressing* 3 SIV
CTL epitopes* (n = 10),
influenza expressing one
SIV CTL epitope (n = 2)
SIVmac251 25
weeks after
first Influenza
inoculation
2 vaccinees previously
reported in Sexton
et al [28]
Influenza
inoculation
of SIV+
macaques
8 PR8 twice, X31 twice
over 18 weeks, 1–2
years after SIV infection
influenza expressing one
SIV CTL epitope (n = 8)
SIVmac251 1–2 years
prior to influenza
inoculation
[28]
Naı¨ve
macaques
8 None NA None Used to study specificity of
influenza specific MHC I tetramer
in absence of influenza infection
SIV vaccinated
macaques
6 None NA None Macaques received DNA and
Fowlpoxvirus prime boost vaccines**.
Used to study SIV CTL responses in
the absence of SIV infection
[39,44]
*All SIV CTL epitopes were minimal epitopes expressed from within the stalk of influenza neuraminidase protein.
**The DNA and fowlpoxvirus vaccines expressed full length SIV Gag and Pol proteins from standard promoters.
doi:10.1371/journal.pone.0032431.t001
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correctly inserted peptide epitope within the expanded virions was
confirmed by sequencing prior to vaccination.
Vaccination and challenge of pigtail macaques
Recombinant and wild-type influenza viruses were administered
to animals by combined intratracheal and intranasal administration
of 108 PFU of influenza virus in PBS as previously described [28].
Successful infection with influenza viruses was confirmed in all
animals by serology and influenza virus RNA recovery in serials
swabs of the upper respiratory tract during infection, kindly
performed by Drs K Laurie and A Hurt at the WHOCollaborative
centre for influenza inMelbourne. Animals were infected with a 104
TCID50 dose of SIVMAC251 either intrarectally or intravaginally as
previously described [45] (kindly provided by Dr N Miller at the
NIH). SIV infection was confirmed in all animals by monitoring
SIV plasma RNA levels as previously described [28].
Intracellular cytokine staining (ICS) assays
The ICS assays involved the addition of 1 mg/ml of co-
stimulatory molecules anti-CD28 and anti-CD49d (Becton Dick-
inson [BD], San Jose, CA), 5–10 mg/ml of Brefeldin A (Sigma, St.
Louis, MO, USA) and/or 5 mg/ml Monesein (eBioscience, San
Diego, CA) to 235 ml of whole blood. Specific peptide antigens
were also added at a concentration of 1 mg/ml unless otherwise
stated. Appropriate controls were set up with an equivalent
concentration of dimethyl sulfoxide (DMSO) (Sigma) and 1 mg/ml
of Staphylococcal enterotoxin B (SEB, Sigma). Where necessary
anti-CD107a FITC or APC-Cy7 (H4B4) (BD, San Jose, CA) was
also added prior to stimulation. Cells were incubated at 37uC with
5% CO2 for 5.5 hours unless otherwise indicated. For assays
gating on tetramer+ cells, Mane-A*10 tetramers were added for
40 minutes at room temperature in the dark. Following this, cells
were incubated with surface antibodies CD8-APC-H7 (SK1),
CD4-PeCy7 (L200), and CD3-Pacific Blue (SP34-4, all BD) for
30 minutes at room temperature in the dark. Red blood cells were
then lysed using 16BD FACsTM Lysing Solution for 10 minutes
and white blood cells permeabilised using 16 FACsTM Permea-
bilising Solution 2 for 10 minutes (BD). Finally, cells were
incubated at room temperature for 1 hour with antibodies for
the intracellular cytokines IFNg-AF700 (B27), TNF-a-PE-Cy7
(mAb11), IL-2-PerCP-Cy5.5 (MQ1-17H12), and MIP-1b-PE
(D21-1351, all BD). Cells were then washed and fixed with 1%
paraformaldehyde (Sigma). Acquisition was performed on the
LSRII flow cytometer (BD) with 16106 lymphocyte events
generally collected. Samples were analysed using FlowJo Version
9.1 (TreeStar, Ashland, USA). Polyfunctional analysis was
performed using PESTLE and SPICE software (kindly supplied
by Dr M Roederer, Vaccine Research Centre, NIH).
Generation of CD8 T cell lines
Influenza-specific CD8 T cell lines were generated as described
previously [35]. Briefly, fresh PBMCs were separated into either
stimulators (16106) or responders (26106, a 1:2 ratio). Responder cells
were resuspended in RPMI plus 15% Fetal calf serum (RF-15) and
placed at 37uCwith 5%CO2 in a 24-well plate while stimulators were
prepared. Stimulator cells were resuspended in 1 mL RF-15
supplemented with 1 mg/ml RA9 peptide and incubated at 37uC
with 5% CO2 for 90 minutes. Cells were then washed 3 times with
RF-15 media and resuspended to a volume of 100 ml that was then
added to the responder cells. At day 3 and day 5 cells were given fresh
RF-15 media containing 50 U/ml recombinant human interleukin-2
(IL-2) and 10 ng/ml human interleukin-7 (IL-7). All cultures were
restimulated at day 7 with peptide pulsed irradiated autologous
PBMCs and checked for specificity via ICS assay at day 10 and 20.
Stimulation assay to establish MHC restriction
Stable cell lines of C1R cells expressing either Mane-A*10 or
Mane-B*02 were generated as previously described [35]. RA9-
specific T cells (responders) cultured for 3 weeks were washed and
resuspended in RF-15 media. Cells were counted and separated in
a 24-well plate to contain 26106 cells per well. The C1R cells
(antigen presenting cells) with either Mane-A*10, Mane-B*02 or no
MHC class I allele, were pulsed with 1 mg/ml RA9 peptide or
DMSO (negative control) and incubated at 37uC with 5% CO2 in
a 24-well plate for 30 minutes. The cells were then washed twice
and 16106 stimulator cells were added to each of the individual
wells. At this point, 10 mg/ml Brefeldin A (Sigma), anti-CD28 and
anti-CD49d costimulatory molecules (BD) were added to each of
the wells and incubated at 37uC with 5% CO2 for 6 hours.
Samples were then processed as in the ICS assay.
Tetramer development
The Mane-A*10-RA9 tetramer reagent was produced using the
JA5 expression plasmids encoding the Mane-A*10 and monkey
b2M as previously described [46]. The vector encoding Mane-A*10
also contained an in-frame fusion of the substrate sequence for
biotinylation by the enzyme BirA. The expression, purification
and refolding of the Mane-A*10 and monkey b2M with RA9
peptide was performed as previously described [46]. Briefly,
proteins were expressed in E. coli BL21 cells and were solubilised
from inclusion bodies. The proteins were refolded with synthetic
RA9 peptide (Genscript, New York, USA) and resulting Mane-
A*10-RA9- b2M complexes were purified by anionic exchange
and gel filtration chromatography. Purified complexes were
biotinylated and tetramerised with the addition of streptavidin-
APC (Invitrogen, CA, USA).
PD-1 and memory marker staining
Thawed PBMCs were stained Live/Dead Fixable Aqua Dead
Cell Stain (Invitrogen, CA, USA) for 30 mins at room temperature
in the dark. Subsequently, the sample was stained with anti-CD3
Pacific Blue (SP34-4), Anti-CD8 APC-H7 (SK1), Anti-CD4 PE-
Cy7 (L200), Anti-CD28 PerCP-Cy5.5 (L293), Anti-CD95 FITC
(DX2, all BD) and anti-CD279 PE (PD-1, J105, eBioscience).
Samples were then stained with a titration-optimized volume of
KP9-APC, KVA10-APC or RA9-APC tetramer for 40 mins at
room temperature in the dark. Then washed with 16PBS and
fixed in 1% formaldehyde and acquired on LSRII flow cytometer
(BD) with 16106 lymphocyte events generally collected.
Tetramer association assay
Thawed PBMCs were stained with Live/Dead Fixable Aqua
Dead Cell Stain (Invitrogen) for 30 mins at room temperature in
the dark. Subsequently, the sample was stained with anti-CD3
Pacific Blue (SP34-4), anti-CD8 APC-H7 (SK1), Anti-CD4 PE-
Cy7 (L200), Anti-CD28 PerCP-Cy5.5 (L293) and Anti-CD95
FITC (DX2, all BD). Samples were then separately incubated with
excess concentrations of KP9-PE and RA9-APC tetramer for
either 1, 3, 10 or 30 mins at room temperature in the dark.
Following incubation all samples were washed with 16 PBS and
fixed with 1% formaldehyde. Samples were acquired on LSRII
flow cytometer (BD) with 16106 lymphocyte events generally
collected.
Results
Influenza NP-specific CD8 T cell response
To analyze influenza-specific CD8 T cells, we first studied 17
Mane-A*10+ pigtail macaques that were infected intranasally and
Virus-Specific CD8 T Cell Responses in Macaques
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intracheally with unmodified influenza viruses or influenza viruses
expressing Mane-A*10-restricted SIV CTL epitopes. Influenza
inoculation used alternating doses of attenuated mouse-adapted
H1N1 (PR8) and H3N2 (X31) strains to ensure efficient antigen
presentation. The infections were asymptomatic but animals
seroconverted and influenza RNA was recovered from serial
swabs of the upper respiratory tract 2 days after inoculation.
To identify common influenza-specific CD8 T cell epitopes, an
intracellular cytokine-staining (ICS) assay was first used to detect
IFN-c and TNF-a expression from CD8 T cells responding to
influenza nucleoprotein (NP) overlapping peptides (Figure 1). The
3 animals (19351, B0547 and B0527) that had the highest
responses to the whole NP peptide pool at 14 days post initial
vaccination with influenza were selected to map influenza NP-
specific CD8 T cell epitopes. The 98 overlapping 17-mer peptides
within the NP peptide pool were divided into 10 sequential sets of
10 17-mers peptides and used to stimulate whole blood from the
selected influenza vaccinated animals in an ICS assay. The
response in all three animals was primarily detected in the 1–10
peptide set (spanning NP amino acids 1 to 62, NP1–62, Figure 1a).
The three animals were then screened for CD8 T cell responses to
each individual 17-mer peptide within the NP1–62 peptide set and
each animal was found to respond to a single 17mer peptide NP10–
27, termed NP3 (Figure 1a).
Fine mapping of NP-specific CD8 T cell response
Fine mapping was subsequently undertaken to determine the
minimal CD8 epitope within the NP10–27 17mer NP3 peptide.
Overlapping 11-mer, 10-mer and 9-mer peptides spanning NP10–
27 were titrated in an ICS assay with one animal (B0547). Cytokine
responses were demonstrated after stimulation with peptides GA11
(NP16–27), EA10 (NP15–27) and RA9 (NP18–27) (Figure 1b). As the
amino acid sequences of these peptides overlap and the most
prominent response was elicited by peptide RA9 we concluded
that the RA9 peptide most likely contained the minimal CD8
epitope. This was further confirmed by subsequent mapping assays
with peptides spanning the C-terminal border of RA9 as well as 8-
mer peptides within RA9, all of which elicited substantially lower
responses than did RA9. Concordant results for fine mapping were
also obtained in another influenza-vaccinated animal (B0527, data
not shown). Once RA9 was determined as a minimal CD8 T cell
epitope, this specific response was analyzed in other influenza-
vaccinated animals. Thirteen of the seventeen influenza vaccinat-
ed animals demonstrated a RA9-specific CD8 T cell response
measuring IFN-c+/TNF-a+ by ICS assay, ranging from 0.02–
0.4%.
Polyfunctional analysis of influenza and SIV CD8 T cell
responses
In animals inoculated with recombinant influenza viruses
expressing SIV CTL epitopes, comparisons could be made
between the influenza-specific and SIV-specific CD8 T cell
responses following vaccination. We used a polyfunctional ICS
assay detecting the effector molecules IFN-c, TNF-a, MIP-1b, IL-
2 and CD107a, to compare the quality of influenza- and SIV-
specific CD8 T cells. Combinatorial analysis was performed on
cells stimulated with the newly mapped influenza NP CD8 T cell
epitope RA9 or the SIV CD8 T cell epitope KVA10 peptides.
Responding CD8 T cells were separated into distinct subsets based
on the combination of effector molecules they produced
(Figure 2a).
The number of effector molecules expressed by the responding
CD8 T cells (their ‘‘polyfunctionality’’) was similar for both the
response to influenza RA9 and SIV KVA10 after the recombinant
influenza-SIV infection, with the majority of responding CD8 T
cells producing two effector molecules (Figure 2b). We also
analyzed 2 other macaques with robust Flu or SIV-specific CTL
response after Influenza-SIV vacation that permitted reliable
division of the total response into multiple segments. We found the
distribution of effector molecules expression was similar to the
example shown in Fig. 2b. Overall, the mean (6SD) of 5, 4, 3, 2, 1
effector molecule expression was 1.0% (60.8%), 18.5% (65.2%),
21.8% (62.6%), 38.8% (63.6%) and 20.0% (67.4%) respectively
in all animals assessed. The pattern of individual effector molecule
production by responding cells showed that the number of
influenza RA9-specific CD8 T cells producing effector molecules
were similar to that of SIV KVA10-specific CD8 T cells producing
effector molecules across 2 animals with both influenza and SIV-
specific CTL responses (Figure 2c). This is consistent with the 2
epitopes being expressed from the same construct. The majority of
responding cells produced the anti-viral cytokine IFN-c or the
degranulation marker CD107a. Interestingly, minimal or no IL-2
was detected in response to either antigen (detected for the SEB
positive control, data not shown) and therefore no CD8 T cells
produced all five effector molecules. As such we did not study IL-2
production in subsequent experiments.
MHC I restriction of influenza-RA9 CTL response
The influenza-inoculated animals studied all shared the MHC-I
allele Mane-A*10 and we therefore investigated whether the
influenza RA9 CTL response was restricted by this allele. The
relatively low levels of memory RA9-specific CD8 T cells in blood
necessitated expansion of these antigen-specific CD8 T cells for
the definitive MHC restriction experiments (Figure 3a). We
cultured PBMC in vitro in the presence of RA9 peptide-pulsed
autologous PMBCs, IL-7 and IL-2 from three influenza vaccinated
animals (B0527, 19351 and B0547) at day 91 post initial
vaccination. In fresh blood, the frequency of RA9-specific CD8
T cells producing IFN-c and TNF-a was approximately 0.04% for
animal B0527 (Figure 3b) and 0.15% for animal B0547. Following
the two-week culture, RA9-specific CD8 T cells expanded to
frequencies of 19% for B0527 and 8.16% for B0547 (Figure 3b).
This not only confirmed the presence of RA9-specific CD8 T cells
in the blood but also facilitated in the restriction of this response to
a given MHC class I allele.
To formally MHC restrict the RA9-specific CD8 T cells,
untransfected control C1R cells and C1R cells stably transfected
with full-length M. nemestrina MHC class I cDNA of either Mane-
A*10 or the irrelevant Mane-B*02 [35] were pulsed with RA9
peptide or DMSO (negative control). These antigen-presenting
cells were incubated with cultured RA9-specific CD8 T cells from
animal B0527. An RA9-specific CD8 T cell response of 1.08% of
CD8 T cells expressing both IFN-c and TNF-a was detected from
the RA9 pulsed Mane-A*10-transfected C1R cells. The control
C1R cells and the irrelevant Mane-B*02-transfected C1R cells
pulsed with either DMSO or RA9 peptide showed a RA9-specific
CD8 T cell response of less than a 0.03% (Figure 3c). The results
demonstrate that Mane-A*10 restricts the influenza RA9 CTL
response.
Generation and validation of Mane A*10-RA9 tetramer
Confirmation of the MHC restriction of influenza RA9-specific
CD8 T cells by Mane-A*10 led us to generate an MHC-I tetramer
to enable further study of the influenza-specific response. A
bacterial expression system was used to produce Mane-A*10
heavy chain and pigtail macaque b2M protein which were
refolded with the RA9 peptide to form a stable MHC-peptide
monomer [46]. The monomer was biotinylated and combined
Virus-Specific CD8 T Cell Responses in Macaques
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with a streptavidin-APC tag and formed a stable MHC class I
tetramer. We evaluated the ability of the Mane-A*10-RA9 tetramer
to bind and recognize RA9-specific CD8 T cells. Mane-A*10-RA9
tetramer staining of frozen PBMCs demonstrated a distinct RA9-
specific CD8 T cell population (0.14% of CD8 T cells) post
vaccination (Figure 4a). No distinct Mane-A*10-RA9 tetramer
positive population was observed in the same animal prior to
influenza vaccination or in an influenza naive Mane-A*10 negative
animal (Figure 4a). To analyze the specificity of this reagent we
studied Mane-A*10-RA9 tetramer staining of peripheral blood cells
from 25 Mane-A*10+ influenza inoculated pigtail macaques and 8
influenza-uninfected animals. The influenza infected animals had
significantly higher frequencies of Mane-A*10-RA9 tetramer
positive cells than uninfected animals (Figure 4b).
The generation of the Mane-A*10-RA9 tetramer allowed us to
analyze influenza-specific CD8 T cells in macaques longitudinally.
We studied frequencies of RA9-specific CD8 T cells following
multiple influenza inoculations. An increase in RA9-specific CD8
T cells was observed for most animals following the first infection
with H1N1 (PR8) influenza which was boosted following
inoculation with H3N2 (X-31) influenza at day 28; with the
number of RA9-specific CD8 T cells in animal B0527 increasing
from 0.08% at day 28 to 0.44% at day 35 (Figure 4c). The
frequency of RA9-specific CD8 T cells further increased after the
fourth influenza inoculation at day 119. Following infection with
SIVmac251 at day 175, a slow decline in the frequency of RA9-
specific CD8 T cells was generally observed in the influenza
vaccinated animals. This was also seen for animal 45418 that was
Figure 1. Mapping of influenza-specific CD8 T cell responses. (A) Gating strategy and IFN-c and TNF-a expression of CD8 T cells in response
to influenza nucleoprotein (NP) from influenza vaccinated 19351, B0547 and B0527, were investigated first by stimulating whole blood with a pool of
98 17-mer peptides overlapping by 12 amino acids (NP peptide pool), then to pools of 10 17-mers and finally to individual 17-mers. A common
response within the first 10 17-mers (NP peptides 1–10) was mapped to the third nucleoprotein peptide (NP peptide #3). (B) Peptide titration
performed on the influenza-vaccinated animal B0547 at day 77 following the initial influenza vaccination. Whole blood was stimulated with 29
peptides (7 11-mers, 9 10-mers, 11 9-mers and 2 8-mers) at diminishing dilutions and responses measured by ICS assay. Peptides yielding responses
above background are shown together with a representative negative peptide (ER9).
doi:10.1371/journal.pone.0032431.g001
Figure 2. Comparison of polyfunctional influenza and SIV-specific CD8 T cell responses following recombinant influenza-SIV
vaccination. Polyfunctional ICS assay was performed on whole blood from the animal 26359 at day 133 after initial influenza vaccination stimulating
with either RA9 or KVA10 peptides. (A) Gating strategy on SEB stimulated sample (B) Summary of functional profile; the proportions of the number of
effector molecules produced by cells when stimulated with either RA9 or KVA10 peptide. (C) The frequency of total effector molecules produced by
RA9 (black bars) and KVA10 (white bars) specific CD8 T cells for animals 26359 and B0526.
doi:10.1371/journal.pone.0032431.g002
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not infected with SIV, suggesting that there was no substantial
SIV-induced change in the frequency of RA9-specific CD8 T cells
(Figure 4c).
Optimization of Mane A*10-RA9 Tetramer-ICS assay
Although the ICS assays allow us to study the functions of T cell
responses to specific antigens, these assays are limited to only
studying the cells that are producing effector molecules. As such
they provide no information about antigen-specific cells that do
not produce a response or may be dysfunctional. Incorporation of
tetramer staining into the ICS assay allows us to home in on
antigen-specific cells as a whole population and investigate how
these cells are responding. However, a frequent problem that
arises with the use of tetramers in ICS assays is the antigen
induced down-regulation of the T-cell receptor (TCR) on antigen-
specific CD8 T cells which greatly reduces the ability of tetramers
to bind to these cells [47,48].
To optimize the use of the Mane-A*10-RA9 tetramer in an ICS
assay we investigated the effect of stimulating the cells with 10-fold
decreasing concentrations of RA9 peptide on the Mane-A*10-RA9
tetramer staining and RA9-specific CD8 T cell cytokine
production (Figure 5a). A clear reduction in Mane-A*10-RA9
tetramer staining is observed as the concentration of the RA9
peptide antigen was increased; from a frequency of 0.71% in the
unstimulated sample to 0.12% in the sample stimulated with
1000 ng/ml of RA9 peptide (Figure 5a). However, the frequency
of Mane-A*10-RA9 tetramer positive cells producing IFN-c and
TNF-a remains similar (approximately 50%) for all RA9 peptide
concentrations except 1 ng/ml where the frequency drops to
23.65% (Figure 5b).
Figure 3. Restriction of RA9 CD8 T cell epitope to Mane-A*10. (A) CD8 T cell response to influenza RA9 peptide in influenza vaccinated animal
26359 (B) Expansion of RA9 specific CD8 T cells. RA9-specific CD8 T cell response in fresh blood is shown in comparison to a 2 week in vitro expansion
as described in methods. (C) Mane-A*10 restriction of RA9 response. Transfected (Mane-A*10 or Mane-B*02) and untransfected C1R cells were pulsed
with either DMSO or RA9 peptide. These C1R cells were incubated separately with in vitro cultured RA9-specific CD8 T cells and IFN-c and TNF-a
expression measured.
doi:10.1371/journal.pone.0032431.g003
Figure 4. CD8 T cell response in influenza-vaccinated animals by Mane-A*10-RA9 tetramer. (A) Mane-A*10-RA9 tetramer was used at a
1:400 dilution on samples from either animal 45418 at influenza vaccinated time-point (day 133) or influenza naı¨ve time-point (day 0), or from an
influenza unvaccinated Mane-A*10 negative animal. (B) The frequency of CD8+ Mane-A*10-RA9 tetramer positive cells were compared in all influenza
vaccinated animals (n = 25) to 13 influenza naı¨ve macaques all samples were 14 days post-final vaccination with influenza virus. All samples were
background corrected and the p-value for the difference between the two groups determined using an unpaired T-test. (C) Thawed PBMC samples
(day 0–126) or whole blood (day 126 onwards) from animals with generally robust influenza-RA9 tetramer responses on initial testing (26359, B0526,
B0527, 45418, 19351 and 19341) were measured for frequency of RA9-specific CD8 T cells via tetramer staining (results are background corrected).
Animals were vaccinated with influenza (either X-31 or PR8 as indicated) at day 0, 28, 56 and 119, then intravaginally challenged at day 175 (Day 0
post-challenge) with SIVmac251. All animals became SIV infected with the exception of 45418(*).
doi:10.1371/journal.pone.0032431.g004
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Interestingly, we also observed distinct differences in the total IFN-
c production when gating on CD8 positive cells that were also CD3
positive compared to all CD8 positive cells regardless of their CD3
phenotype. At higher RA9 peptide concentrations (1000 ng/ml and
100 ng/ml) the frequency of IFN-c producing RA9-specific CD8 T
cells is greater when CD8 T cells are not gated according to CD3
Figure 5. T-cell receptor down-regulation in response to antigenic stimulation. Tetramer-ICS assay performed using blood from an animal
inoculated with influenza viruses (animal #26359) by stimulating blood cells with either DMSO (unstimulated) or decreasing concentrations of RA9
peptide (1000 ng/ml, 100 ng/ml, 10 ng/ml and 1 ng/ml). (A) Loss of tetramer+ cells following in vitro stimulation with high RA9 peptide
concentrations. Cells were gated on CD3+CD8+ followed by gating on influenza RA9 tetramer positive cells. (B) Higher cytokine expression in
influenza RA9-specific cells following stimulation with .10 ng/ml of RA9. The IFN-c and TNF-a production from gated tetramer+ RA9-specific cells
from panel (A) were compared between the decreasing concentrations of peptide. (C) Samples were analysed via two alternative gating strategies;
gating on CD3+CD8+ cells, followed by gating on the total IFN-c. Alternatively we gated on CD3 negative and positive cells (CD3+/2) and then gated
on CD8+ cells, and measured the total IFN-c production from these cells. Cells from this strategy were plotted as IFN-c versus RA9-tetramer positive
cells.
doi:10.1371/journal.pone.0032431.g005
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phenotype (Figure 5c). Furthermore, when we looked at Mane-A*10-
RA9 tetramer staining of these IFN-c producing CD8 cells we
observed that Mane-A*10-RA9 tetramer positive cells only represent
approximately one quarter of the total IFN-c producing cells at these
peptide concentrations. Whereas at lower RA9 peptide concentra-
tions (10 ng/ml and 1 ng/ml), the CD3 phenotype does not appear
to affect the frequency of IFN-c producing CD8 cells and the
proportion of these cells that are Mane-A*10-RA9 tetramer positive
cells is greater than 60%. Our results suggest that in conjugation with
TCR down-regulation there is also an associated down-regulation of
the CD3 molecules of antigen-specific cells in the ICS assay. The
effects of TCR and CD3 downregulation were limited when the
concentration of stimulating peptide was reduced to 10 ng/ml with-
out impacting greatly on the effector molecule production. Further
experiments on effector molecule expression on tetramer positive
CD8 T cells were performed with 10 ng/ml antigen stimulation.
CD8 T cell responses to influenza and SIV using tetramer-
ICS assay after influenza infection
Having optimized the use of the Mane-A*10-RA9 tetramer in
the ICS assay we used this assay to determine the polyfunctionality
of influenza- and SIV-specific CD8 T cell responses after
influenza-SIV vaccination. As seen with the standard ICS assay
(Figure 2) the overall pattern of effector molecule expression from
CD8 T cells in response to either influenza RA9 or SIV KVA10
were similar (Figure 6a and 6b). This is consistent with the epitopes
being expressed from the same vector and consistent with other
studies using vaccinia vectors [49,50]. Interestingly, the incorpo-
ration of tetramer in the ICS assay also allowed us to determine
that close to half of the RA9- and KVA10-specific CD8 T cells did
not produce any of the studied effectors molecules (as shown by
pale section of pie chart in Fig. 6a), with 3–15% producing one
effector molecule and very few cells (,1%) producing all 4 effector
molecules. These studies were repeated in another 3 animals with
similar results, where the most common number of effector
molecule expressed was none, 11–15% of cells expressed one and
,1% producing all 4 effector molecules. The pattern of expression
of effector molecule expression was also similar across another 3
animals, with MIP1b the least commonly expressed (,2% of total)
and IFNc, TNFa and CD107a all of reasonable expression levels
(47.9%, 20.2% and 31.4% of total respectively).
The kinetics of the in vitro effector molecule response has been
proposed to reflect the ability of CD8 T cells to rapidly respond in
vitro [21]. We therefore analyzed the kinetics of the effector molecule
response following recombinant influenza-SIV inoculation by
stopping the assay after 1, 5.5 or 7 hours of antigen stimulation.
Results are shown for one animal that had robust RA9- and KVA10
responses and allowed analyses or responses developing over time
(Figure 6c). Again similar profiles were seen for both the RA9- and
KVA10-specific CD8 T cell response, with CD107a being
produced after just 1 hour of peptide stimulation, followed by
IFN-c and TNF-a detectable after 5.5 hours and further increasing
after 7 hours of antigen stimulation. This kinetic study was repeated
in another influenza-SIV vaccinated animal and a similar pattern of
effector molecule expression observed in the influenza CTL
responses, with CD107a expression clearly detected at 1 hr, but
the TNFa/IFNc response only detectable at 5.5 h and increasing
through to 7 h after stimulation (data not shown).
Polyfunctionality of influenza and SIV-specific CD8 T cell
responses following SIV infection
The validation of the use of tetramers in the ICS assay allowed
us to assess the polyfunctionality of the memory influenza-specific
CD8 T cell response and the effector SIV-specific CD8 T cell
response following acute and chronic SIV infection. The
challenged animals all became infected with SIVmac251 after
inoculation and had a mean peak SIV plasma RNA level at 2
weeks after challenge of 7.47 (61.28) log10 copies/ml and a mean
set point viral load from weeks 5–10 post-SIV infection of 6.29
(60.25) log10 copies/ml. We analyzed in detail the proportion of
CD8 T cells producing a number of effector molecules (IFN-c,
TNF-a, CD107a and MIP-1b) at different time-points following
SIV challenge in fresh blood samples from one animal with robust
influenza and SIV-specific CTL responses (Figure 7). Around the
time of SIV challenge (and as discussed for figure 6a), the profiles
of influenza RA9 and SIV KVA10 responses were similar (shown
for comparison as the top pie charts in Figure 7). Throughout the
first 7 weeks of SIV infection, the RA9-specific CD8 T cell
polyfunctional response profile was relatively constant, with just
under half of the RA9-specific CD8 T cells producing none of the
studied effector molecules. In contrast, the SIV KVA10-specific
CD8 T cell response became less functional by day 49 after SIV
infection, with the proportion of KVA10-specific CD8 T cells not
producing any effector molecules increasing to well over half of the
tetramer+ cells through day 49 after infection. The reduction in
effector molecule expression was largest for the CD107a+IFN-
c+TNF-a+ triple positive cells, which decreased from 28.5% of the
tetramer+ population at day 2 to only 5.7% by day 49. Although
no response was detected to SIV KP9 prior to SIV challenge, a
similar trend was seen with the KP9-specific CD8 T cells during
the course of SIV infection, which exhibited a less functional
response at day 49 compared to the response at day 17. In another
3 animals studied for SIV KP9 CTL responses after challenge, the
proportion of KP9-specific cells not expressing any effector
molecules was also high at over 50% (range 55–75%) of the
tetramer+ cells within 17–35 days after SIV infection reflecting
poor effector molecule expression by SIV-specific CTLs after SIV
infection.
Sensitivity and avidity of influenza and SIV-specific CD8
T-cell responses following SIV infection
The ability of CD8 T cells to respond to low levels of peptide
antigens has been shown to play a role in recovery from viral
infections [13,22]. This peptide sensitivity has been suggested to be
an important aspect of CD8 T cell quality [51]. The quality of
influenza- and SIV-specific CTL responses was therefore exam-
ined by assessing the CD8 T cell response after stimulation with
different concentrations of peptide at different time-points
following SIV infection in fresh blood samples from one animal
with robust influenza and SIV-specific CTL responses (Figure 8a).
Prior to infection (day 0), similar proportions of both influenza
RA9- and SIV KVA10 tetramer+ CD8 T cells produced IFN-c
and TNF-a across a range of peptide concentrations (square
symbols in figure 8b). The proportion of influenza RA9 tetramer+
CD8 T cells producing IFN-c and TNF-a at low levels of antigen
stimulation was maintained at high levels through to day 14 of SIV
infection with a modest drop off by day 49 (closed symbols in
figure 8b). In contrast, the SIV KVA10 tetramer+ CD8 T cells
almost completely lose the ability to produce IFN-c and TNF-a
after low levels of antigen stimulation by day 14 and this is
maintained through day 49 of infection. This experiment was
repeated in an additional influenza-SIV vaccinated animal after
SIV infection and we again observed a substantial reduction in
cytokine expression by SIV KVA10 tetramer+ cells by day 14–49
after SIV infection expression at low peptide concentrations (data
not shown).
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Another important measure of virus specific CD8 T-cell
response quality is the avidity of T-cells for their MHC/peptide
tetramer prior to and following challenge. The avidity of influenza
and SIV specific CD8 T-cells for their respective MHC-tetramer/
peptide complexes was measured by the tetramer association assay
that incubates PBMCs for different lengths of time in the presence
Figure 6. Comparison of tetramer positive influenza and SIV-specific CD8 T cell responses following recombinant influenza-SIV
vaccination. Polyfunctional-tetramer ICS assay was performed on whole blood from day 0 post SIV infection stimulating with either RA9 or KVA10
peptides. (A) Summary of functional profile; the proportions of the number of effector molecules produced by antigen specific CD8 T cells when
stimulated with either RA9 or KVA10 peptide. (B) The frequency of total effector molecules produced by RA9 (black) and KVA10 (white) specific CD8 T
cells. Results are shown for 2 separate animals. (C) Comparison of the kinetics of effector molecule for RA9 (filled) versus KVA10 (open) at day 5 post
SIV infection.
doi:10.1371/journal.pone.0032431.g006
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of excess concentrations of MHC tetramer. Virus-specific CD8 T-
cells that rapidly bind tetramer can be characterized as higher
avidity than those that bind only after a longer incubation. We
studied both influenza RA9 and SIV KP9 tetramer positive cells in
the same PBMC samples from 4 influenza inoculated, SIV-
infected macaques. In each case, the influenza-specific CD8 T-
cells had significantly higher tetramer avidity compared to SIV-
specific CD8 T-cells (Figure 8c. p = 0.028 at 3 minutes of
incubation, Ranksum test).
Exhaustion markers of influenza and SIV-specific CD8 T-
cells following SIV infection
The difference in polyfunctionality and avidity of SIV-specific
CD8 T-cells compared to influenza-specific CD8 T-cells could
potentially be explained by the exhaustion of SIV-specific CD8 T-
cells. The exhaustion of virus-specific CD8 T-cells has been shown
previously to correlate closely with changes in expression of the
marker PD-1 [24]. We therefore studied PD-1 expression on
tetramer+ influenza- or SIV-specific CD8 T cells in PBMC from
Mane-A*10+ pigtail macaques across a wide ranges of infection
and vaccination scenarios. The PD-1 expression on influenza-
specific CD8 T-cells from animals either influenza vaccinated,
influenza vaccinated following SIV infection or influenza vacci-
nated then SIV challenged remained similar (Figure 9a). To study
KP9 SIV-specific CD8 T-cells in the absence of SIV infection we
analyzed stored PBMC from either recombinant influenza-SIV
inoculated animals prior to SIV infection or from prior studies of
DNA and fowlpox virus prime-boost immunization expressing
SIV Gag prior to SIV infection [40,45]. The PD-1 expression on
vaccine-induced SIV KP9-specific CD8 T-cells was significantly
less than on KP9-specific CD8 T cell from SIV infected animals
(Figure 9a). Further, animals that received an influenza-SIV
vaccination only after SIV infection also had a greater PD-1
expression than SIV vaccinated uninfected animals (Figure 9a).
This suggests that the RA9 influenza-specific CD8 T-cell responses
do not express the same amount of the exhaustion marker PD-1
compared to the KP9 SIV-specific CD8 T-cell response following
SIV infection. For comparison, the magnitude of the influenza-
specific and SIV-specific CTL responses at the times measured
adjacent to the PD-1 expression was also assessed (Figure 9b).
There were only modest non-significant differences in the
magnitude of the responses across the groups.
The dysfunction and exhaustion of SIV-specific CD8 T-cells is
likely explained by chronic stimulation of SIV-specific CD8 T-cells
following SIV infection. One marker of chronic antigenic
stimulation is loss of the expression of the costimulatory molecule
CD28 [52,53]. We therefore studied CD28 expression on
influenza and SIV-specific CD8 T-cells in stored PBMC from
animals inoculated with recombinant influenza-SIV viruses prior
to and after SIV infection. We found that influenza-specific CD8
T-cells express similar levels of CD28 before and after infection
with SIV (Figure 9b). Vaccine-induced SIV-specific CD8 T-cells
express similar levels of CD28 to influenza-specific CD8 T-cells
prior to SIV infection, but following infection CD28 expression on
the effector SIV-specific CD8 T-cells decreases substantially
(Figure 9b).
Discussion
Improved primate models are needed to directly compare CD8
T cell immunity that assist in resolving acute viral pathogens and
CD8+ T cell immunity that fails to resolve chronic viral pathogens
within the one host. Macaques are a potentially useful non-human
primate model to study important viral pathogens such as
influenza and HIV. We recently developed an influenza-SIV
vaccination model of Mane-A*10+ pigtail macaques [28] and used
this to study both influenza-specific and SIV-specific CD8 T cells.
A common influenza nucleoprotein-specific CD8 T cell response
was mapped to a minimal epitope (termed RA9). The RA9 CD8 T
cell response was restricted by Mane-A*10 and a Mane-A*10-RA9
tetramer was developed to study this response in more detail. We
found that the memory RA9 influenza-specific CD8 T cell
response following resolution of influenza infection, in comparison
to effector SIV-specific CD8 T cell responses during chronic
persistent SIV replication, maintained a highly functional profile
in terms of the multitude of effector molecule expression, avidity
and expression of exhaustion markers despite SIV infection.
The mapping of an influenza CD8 T cell epitope restricted by a
common MHC I allele and generation of a MHC-I tetramer for
this epitope is an important advance for influenza studies in
macaques. The utility of a functional RA9 specific CD8 T-cell
response to control influenza infection can now be analyzed in
future studies of pathogenic macaque influenza infection.
Interestingly, of the 4 CD8 T cell epitopes now known to be
restricted by Mane-A*10 (RA9, KP9, KVA10, KSA10), only RA9
does not start with a double lysine (KK) motif [54]. We are
planning structural studies to understand how all these epitopes
are accommodated and presented by Mane-A*10. The develop-
ment of a more refined motif for epitopes capable of binding to
Mane-A*10 should enable scanning of viral genomes of influenza,
SIV and other pathogens for other Mane-A*10-presented epitopes.
An improved understanding of the presentation of Mane-A*10
epitopes should also lead towards more refined analyses of the
evolution of viral escape mutations [33,35].
Figure 7. Comparison of polyfunctionality of influenza and
SIV-specific CD8 T cells during SIV infection. Polyfunctional
tetramer ICS assay was performed on whole blood from the animal
26359 at days 0, 17, 35, and 49 post SIV infection, stimulating with
10 ng/ml of either RA9, KVA10 or KP9. The pie-charts show the
proportions of tetramer positive antigen-specific CD8 T cells producing
0–4 effector molecules. KP9-specific CD8 T cells were not detectable at
day 0 post SIV infection.
doi:10.1371/journal.pone.0032431.g007
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Figure 8. Comparison of sensitivity and avidity of influenza and SIV-specific CD8 T cells during SIV infection. (A) and (B) Comparison
of re-stimulation induced cytokine production. An ICS assay was performed on whole blood from the animal 26359 at days 0, 14, and 49 post SIV
infection, stimulating with decreasing concentrations of peptide (1000 ng/ml, 100 ng/ml, 10 ng/ml and 1 ng/ml) of either RA9 or KVA10 peptide.
Function of the CD8 T-cells was assessed for IFN-c expression (A) and TNF-a expression (B). (C) Comparison of relative levels of tetramer binding
following incubation of PBMC samples from macaques with chronic SIV-infected that had been previously inoculated with influenza (n = 5) with
either RA9-Mane-A*10 (circle) or KP9-Mane-A*10 (square) tetramer for 1, 3, 10 or 30 mins. Maximum tetramer binding was determined by the relative
tetramer binding compared to 30 min incubated sample.
doi:10.1371/journal.pone.0032431.g008
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Influenza-specific CD8 T cells have been extensively studied in
mice and humans in recent years [55,56] but non-human primate
and ferret models of influenza have lagged behind in terms of
sophisticated immunologic reagents [30,57,58]. The development
of an MHC tetramer to track these cells in non-human primates is
an important advance. We used the Mane-A*10-RA9 tetramer to
track the influenza CD8 T cell response over time, enabling an
analysis of cells that did not express any of the effector molecules
studied. Around half of influenza-specific CD8 T cells we detected
with the tetramer did not express any of 4 effector molecules after
the vaccination process; these cells would not be detected by most
standard Elispot and ICS techniques. We performed detailed
kinetic and peptide-responsiveness assays on tetramer-positive cells
within fresh macaque blood samples, although the conclusions for
some analyses should be tempered by the technical difficulties in
studying fresh samples from multiple animals concurrently. In
general however, the functionality in terms of effector molecule
expression of the SIV-specific CD8 T cells induced by the SIV
epitope encoded within influenza was similar to that of the
memory influenza specific CD8 T cells prior to SIV infection, but
the chronically activated SIV-specific CD8 T cells rapidly became
less functional within weeks after ongoing SIV infection.
Our results are in agreement with the multiple dysfunctions
frequently observed in SIV-specific CD8 T cells in macaques and
HIV-specific CD8 T cells in humans observed during the course of
infection [12,14]. The retention of functions by the influenza-
specific CD8 T cells during early SIV infection was somewhat
surprising given the broad immunodeficiency induced by SIV.
Indeed it was recently shown that some influenza strains can be
more pathogenic in HIV-infected humans compared to HIV-
negative humans, suggesting influenza-specific immunity is
impaired during HIV infection [59]. On the other hand, in our
study the SIV-specific CD8 T cells are actively responding to a
persistent viral infection whereas the influenza-specific CD8 T
cells are no longer responding to an antigenic challenge. This
could reflect dysfunction of the SIV-specific CD8 T-cells from
chronic antigen-induced stimulation inducing the down-regulation
of the T cell receptor observed after in vitro antigen stimulation.
Future studies of influenza infection of SIV-infected macaques can
now further analyze the effect of SIV infection on the developing
influenza-specific CD8 T cell response. This has implications for
the effectiveness of influenza vaccination in the setting of HIV
infection [60].
The maintenance of a more functional profile by influenza-
specific CD8 T cells despite SIV infection in this model likely
reflects the efficient priming of this response and the lack of
persistent antigenic stimulation [24,52,61]. Influenza-specific CD8
T cells had minimal or no increase in their expression of the
exhaustion marker PD-1 in contrast to SIV-specific CD8 T-cells
following SIV infection. In addition, expression of the CD28
costimulatory molecule expression decreased on SIV-specific CD8
T-cells but was maintained on influenza-specific CD8 T-cells.
Taken together, the results suggest that chronic antigen stimula-
tion has led to the dysfunctional SIV-specific CTL response but
that in the absence of chronic antigenic stimulation the function of
the memory influenza-specific CTL response is preserved.
In summary, this study develops important reagents to study
influenza-specific CD8 T cells in pigtail macaques we show that
effector SIV-specific, but not memory influenza-specific CD8 T
cells, rapidly become dysfunctional during SIV infection. Our
work suggests that vaccine or immunotherapy strategies to
maintain more functional HIV-specific CD8 T cells during HIV
infection should be of value in achieving better virologic control
and delaying HIV disease.
Acknowledgments
We thank Mandvi Bardwaj, Shielajen Alcantara, Caroline Fernandez,
Wendy Winnall, Jie Lin, Jacqueline Widjaja, Darryl Johnson and Chris
Harpur at the University of Melbourne and Janaki Amin at UNSW for
expert assistance.
Author Contributions
Conceived and designed the experiments: SJ JCR AGB SJK AS.
Performed the experiments: SJ. Analyzed the data: SJ. Contributed
reagents/materials/analysis tools: RDR JS LS. Wrote the paper: SJ SJK
AS.
References
1. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in
plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-
infected macaques. J Exp Med 189: 991–998.
2. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, et al. (2004)
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus
replication in a preclinical AIDS vaccine trial. J Exp Med 199: 1709–1718.
3. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, et al. (1988) HIV-1
gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus
and synthetic peptides. Nature 336: 484–487.
4. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999)
Control of viremia in simian immunodeficiency virus infection by CD8+
lymphocytes. Science 283: 857–860.
5. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral
pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during
primary infection demonstrated by rapid selection of CTL escape virus. Nat
Med 3: 205–211.
6. Evans DT, O’Connor DH, Jing P, Dzuris JL, Sidney J, et al. (1999) Virus-
specific cytotoxic T-lymphocyte responses select for amino-acid variation in
simian immunodeficiency virus Env and Nef. Nat Med 5: 1270–1276.
7. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, et al. (2005) Rapid viral
escape at an immunodominant simian-human immunodeficiency virus cytotoxic
T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79: 5721–5731.
8. Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, et al. (1996) Novel, cross-
restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow
progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 12: 1691–1698.
9. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al.
(2000) HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A
97: 2709–2714.
10. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, et al. (2002) Cross-
reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow
progressors with B*57. AIDS 16: 961–972.
Figure 9. Exhaustion marker expression on influenza and SIV-specific CD8 T-cells. (A) Comparison of PD-1 expression on influenza RA9
tetramer-positive CD8 T-cells (top) and SIV KP9 tetramer-positive CD8 T-cells (bottom). RA9-tetramer staining was performed on frozen PBMC
samples from animals either influenza vaccinated (influenza vaccinated after SIV infection or influenza vaccinated then SIV infected. Samples were
typically tested at around 2–3 weeks post final vaccination. Tetramer staining of KP9-positive CD8 T-cells was performed on frozen PBMC samples
from animals either, SIV vaccinated, SIV infected then vaccinated or SIV infected. Samples were compared using a One-way ANOVA with overall
p = 0.956 for the influenza-RA9 comparison and p,0.001 for SIV-KP9 comparison (B) Magnitude of the tetramer responses in the same groups as for
(B). Samples were compared as above using a One-way ANOVA overall p.0.05 for both influenza-RA9 comparison and SIV-KP9 comparison.
(C) Frozen PBMC samples from two animals inoculated with recombinant influenza-SIV viruses (animals 1335 and 2374) were stained for CD28
expression on RA9 or KP9 tetramer positive cells prior to and following challenge with SIVmac251.
doi:10.1371/journal.pone.0032431.g009
Virus-Specific CD8 T Cell Responses in Macaques
PLoS ONE | www.plosone.org 15 March 2012 | Volume 7 | Issue 3 | e32431
11. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence
of HLA-B57 on clinical presentation and viral control during acute HIV-1
infection. AIDS 17: 2581–2591.
12. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic
granule loading of CD8+ T cells is required for HIV-infected cell elimination
associated with immune control. Immunity 29: 1009–1021.
13. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior
control of HIV-1 replication by CD8+ T cells is reflected by their avidity,
polyfunctionality, and clonal turnover. J Exp Med 204: 2473–2485.
14. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV
nonprogressors preferentially maintain highly functional HIV-specific CD8+ T
cells. Blood 107: 4781–4789.
15. Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, et al. (2010) CD8+
lymphocytes control viral replication in SIVmac239-infected rhesus macaques
without decreasing the lifespan of productively infected cells. PLoS Pathog 6:
e1000747.
16. Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, et al. (2010) In
vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance
of productively infected cells. PLoS Pathog 6: e1000748.
17. Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA, et al. (2011) A
comparative analysis of HIV-specific mucosal/systemic T cell immunity and
avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisa-
tions. Vaccine 29: 3008–3020.
18. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, et al. (2007)
Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+
T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 178:
2370–2379.
19. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen
sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-
suppressive activity. Blood 113: 6351–6360.
20. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009)
Effector memory T cell responses are associated with protection of rhesus
monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15:
293–299.
21. Rollman E, Smith MZ, Brooks AG, Purcell DF, Zuber B, et al. (2007) Killing
kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for
HIV vaccine strategies. J Immunol 179: 4571–4579.
22. Mueller SN, Langley WA, Li G, Garcia-Sastre A, Webby RJ, et al. (2010)
Qualitatively different memory CD8+ T cells are generated after lymphocytic
choriomeningitis virus and influenza virus infections. J Immunol 185:
2182–2190.
23. Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, et al. (2011)
Phenotype, function, and gene expression profiles of programmed death-1(hi)
CD8 T cells in healthy human adults. J Immunol 186: 4200–4212.
24. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, et al. (2007)
SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have
impaired proliferative capacity in acute and chronic SIVmac251 infection.
Blood 110: 928–936.
25. Klatt NR, Vinton CL, Lynch RM, Canary LA, Ho J, et al. (2011) SIV infection
of rhesus macaques results in dysfunctional T- and B-cell responses to neo and
recall Leishmania major vaccination. Blood 118(22): 5803–5812.
26. Tsukamoto T, Takeda A, Yamamoto T, Yamamoto H, Kawada M, et al. (2009)
Impact of cytotoxic-T-lymphocyte memory induction without virus-specific
CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in
rhesus macaques. J Virol 83: 9339–9346.
27. Yap KL, Ada GL, McKenzie IF (1978) Transfer of specific cytotoxic T
lymphocytes protects mice inoculated with influenza virus. Nature 273:
238–239.
28. Sexton A, De Rose R, Reece JC, Alcantara S, Loh L, et al. (2009) Evaluation of
recombinant influenza virus-simian immunodeficiency virus vaccines in
macaques. J Virol 83: 7619–7628.
29. Carroll TD, Matzinger SR, Fritts L, McChesney MB, Miller CJ (2011) Memory
B cells and CD8 lymphocytes do not control seasonal influenza A virus
replication after homologous re-challenge of rhesus macaques. PLoS One 6:
e21756.
30. Lay M, Callejo B, Chang S, Hong DK, Lewis DB, et al. (2009) Cationic lipid/
DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone)
increases antibody response, cellular immunity, and antigenically drifted
protection. Vaccine 27: 3811–3820.
31. Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, et al. (2011)
Alphavirus replicon-based adjuvants enhance the immunogenicity and effec-
tiveness of Fluzone (R) in rhesus macaques. Vaccine 29: 931–940.
32. Weinfurter JT, Brunner K, Capuano SV, 3rd, Li C, Broman KW, et al. (2011)
Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1
influenza virus in nonhuman primates. PLoS Pathog 7: e1002381.
33. Smith MZ, Asher TE, Venturi V, Davenport MP, Douek DC, et al. (2008)
Limited maintenance of vaccine-induced simian immunodeficiency virus-specific
CD8 T-cell receptor clonotypes after virus challenge. J Virol 82: 7357–7368.
34. De Rose R, Mason RD, Loh L, Peut V, Smith MZ, et al. (2008) Safety,
immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in
macaques. J Med Primatol 37 Suppl 2: 69–78.
35. Smith MZ, Dale CJ, De Rose R, Stratov I, Fernandez CS, et al. (2005) Analysis
of pigtail macaque major histocompatibility complex class I molecules presenting
immunodominant simian immunodeficiency virus epitopes. J Virol 79: 684–695.
36. Harari A, Enders FB, Cellerai C, Bart PA, Pantaleo G (2009) Distinct profiles of
cytotoxic granules in memory CD8 T cells correlate with function, differenti-
ation stage, and antigen exposure. J Virol 83: 2862–2871.
37. O’Leary CE, Wiseman RW, Karl JA, Bimber BN, Lank SM, et al. (2009)
Identification of novel MHC class I sequences in pig-tailed macaques by
amplicon pyrosequencing and full-length cDNA cloning and sequencing.
Immunogenetics 61: 689–701.
38. Pratt BF, O’Connor DH, Lafont BA, Mankowski JL, Fernandez CS, et al. (2006)
MHC class I allele frequencies in pigtail macaques of diverse origin.
Immunogenetics 58: 995–1001.
39. Fernandez CS, Reece JC, Saepuloh U, De Rose R, Ishkandriati D, et al. (2011)
Screening and confirmatory testing of MHC class I alleles in pig-tailed
macaques. Immunogenetics 63: 511–521.
40. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, et al. (2007)
Comparative efficacy of subtype AE simian-human immunodeficiency virus
priming and boosting vaccines in pigtail macaques. J Virol 81: 292–300.
41. Andreansky SS, Stambas J, Thomas PG, Xie W, Webby RJ, et al. (2005)
Consequences of immunodominant epitope deletion for minor influenza virus-
specific CD8+-T-cell responses. J Virol 79: 4329–4339.
42. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG (2000) A DNA
transfection system for generation of influenza A virus from eight plasmids. Proc
Natl Acad Sci U S A 97: 6108–6113.
43. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, et al. (2006) A
virus-specific CD8+ T cell immunodominance hierarchy determined by antigen
dose and precursor frequencies. Proc Natl Acad Sci U S A 103: 994–999.
44. Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, et al. (2003)
Protection and compensation in the influenza virus-specific CD8+ T cell
response. Proc Natl Acad Sci U S A 100: 7235–7240.
45. Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, et al. (2005) Mucosally-
administered human-simian immunodeficiency virus DNA and fowlpoxvirus-
based recombinant vaccines reduce acute phase viral replication in macaques
following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23:
5009–5021.
46. Smith MZ, Fernandez CS, Chung A, Dale CJ, De Rose R, et al. (2005) The
pigtail macaque MHC class I allele Mane-A*10 presents an immundominant
SIV Gag epitope: identification, tetramer development and implications of
immune escape and reversion. J Med Primatol 34: 282–293.
47. Valitutti S, Muller S, Dessing M, Lanzavecchia A (1996) Different responses are
elicited in cytotoxic T lymphocytes by different levels of T cell receptor
occupancy. J Exp Med 183: 1917–1921.
48. Appay V, Rowland-Jones SL (2002) The assessment of antigen-specific CD8+ T
cells through the combination of MHC class I tetramer and intracellular
staining. J Immunol Methods 268: 9–19.
49. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007)
Immunization with vaccinia virus induces polyfunctional and phenotypically
distinctive CD8(+) T cell responses. J Exp Med 204: 1405–1416.
50. Mason RD, Alcantara S, Peut V, Loh L, Lifson JD, et al. (2009) Inactivated
simian immunodeficiency virus-pulsed autologous fresh blood cells as an
immunotherapy strategy. J Virol 83: 1501–1510.
51. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, et al. (2007) Skewed
association of polyfunctional antigen-specific CD8 T cell populations with HLA-
B genotype. Proc Natl Acad Sci U S A 104: 16233–16238.
52. Gamberg J, Pardoe I, Bowmer MI, Howley C, Grant M (2004) Lack of CD28
expression on HIV-specific cytotoxic T lymphocytes is associated with disease
progression. Immunol Cell Biol 82: 38–46.
53. Garber DA, Silvestri G, Barry AP, Fedanov A, Kozyr N, et al. (2004) Blockade
of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in
control of SIV replication. J Clin Invest 113: 836–845.
54. Mason RD, De Rose R, Kent SJ (2009) Differential patterns of immune escape
at Tat-specific cytotoxic T cell epitopes in pigtail macaques. Virology 388:
315–323.
55. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, et al. (2010) Cross-
reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-
1918 influenza A viruses. Proc Natl Acad Sci U S A 107: 12599–12604.
56. Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, et al. (2008)
Killer T cells in influenza. Pharmacol Ther 120: 186–196.
57. Carroll TD, Matzinger SR, Genesca M, Fritts L, Colon R, et al. (2008)
Interferon-induced expression of MxA in the respiratory tract of rhesus
macaques is suppressed by influenza virus replication. J Immunol 180:
2385–2395.
58. Hurt AC, Nor’e SS, McCaw JM, Fryer HR, Mosse J, et al. (2010) Assessing the
viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a
competitive-mixtures model. J Virol 84: 9427–9438.
59. Perez CM, Dominguez MI, Ceballos ME, Moreno C, Labarca JA, et al. (2010)
Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS 24: 2867–2869.
60. Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, et al.
(2011) Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected
adults. Vaccine 29: 9224–9228.
61. Kaufmann DE, Walker BD (2009) PD-1 and CTLA-4 inhibitory cosignaling
pathways in HIV infection and the potential for therapeutic intervention.
J Immunol 182: 5891–5897.
Virus-Specific CD8 T Cell Responses in Macaques
PLoS ONE | www.plosone.org 16 March 2012 | Volume 7 | Issue 3 | e32431
Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or
emailed to multiple sites or posted to a listserv without the copyright holder's express written permission.
However, users may print, download, or email articles for individual use.
